Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.70    0.15 (9.68%)
Bid:
1.70
Ask:
1.99
Spread: 0.29 (17.059%)
Market Cap: £5.96m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Total Voting Rights

31 Oct 2008 12:10

RNS Number : 1558H
Proteome Sciences PLC
31 October 2008
 



Total Voting Rights

31st October, 2008

Proteome Sciences plc ("Proteome Sciences" or the "Company")

In conformity with the Disclosure and Transparency Rule 5.6.1, the Company notifies the market of the following: 

 

As at the date of this announcement, the Company's issued share capital consists of 132,803,571 ordinary shares with a nominal value of 1 pence each ("Ordinary Shares"), with voting rights. The Company does not hold any Ordinary Shares in Treasury. 

 

Therefore, the total number of Ordinary Shares with voting rights is 132,803,571

 

The above figure of 132,803,571 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules. 

For further information please contact: 

Christopher Pearce or James Malthouse

Proteome Sciences plc

Tel: +44 (0)1932 865065

Claes Spång

Teathers Limited

Tel: +44 (0)207 426 9000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRBDBDGCGXGGIB
Date   Source Headline
26th May 20229:04 amRNSChange of Registered Office
16th May 20221:24 pmRNSResult of AGM
16th May 20227:00 amRNSAGM Statement
12th May 20227:00 amRNSSubstantial Contract Win
26th Apr 20224:45 pmRNSDirector/PDMR Shareholding
21st Apr 20225:13 pmRNSDirector/PDMR Shareholding
11th Apr 20227:00 amRNSInvestor Presentation
1st Apr 20226:01 pmRNSDirector shareholding
31st Mar 20227:09 amRNSFinal Results
30th Mar 202211:24 amRNSLoan amendment
29th Mar 20227:00 amRNSNotice of Results
16th Feb 20224:40 pmRNSSecond Price Monitoring Extn
16th Feb 20224:35 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSTrading Update
31st Dec 202112:36 pmRNSPrice Monitoring Extension
20th Dec 20217:00 amRNSSubstantial Contract Win
9th Dec 20214:41 pmRNSSecond Price Monitoring Extn
9th Dec 20214:36 pmRNSPrice Monitoring Extension
29th Nov 20214:36 pmRNSPrice Monitoring Extension
26th Nov 20214:36 pmRNSPrice Monitoring Extension
5th Nov 20217:00 amRNSPRM,INmune Bio presenting biomarker discovery data
3rd Nov 20214:41 pmRNSSecond Price Monitoring Extn
3rd Nov 20214:36 pmRNSPrice Monitoring Extension
26th Aug 20214:40 pmRNSSecond Price Monitoring Extn
26th Aug 20214:36 pmRNSPrice Monitoring Extension
29th Jul 20217:00 amRNSInterim Results
15th Jul 20214:41 pmRNSSecond Price Monitoring Extn
15th Jul 20214:35 pmRNSPrice Monitoring Extension
18th Jun 20211:14 pmRNSLoan amendment
8th Jun 202112:54 pmRNSGrant of Options and PDMR/director shareholdings
19th May 20216:01 pmRNSIssuance of key TMT Patent
18th May 20219:48 amRNSChange of Registered Office
12th May 20214:36 pmRNSPrice Monitoring Extension
7th May 20214:41 pmRNSSecond Price Monitoring Extn
7th May 20214:36 pmRNSPrice Monitoring Extension
6th May 20214:41 pmRNSSecond Price Monitoring Extn
6th May 20214:35 pmRNSPrice Monitoring Extension
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202111:57 amRNSResult of AGM
5th May 202111:00 amRNSAGM Statement
27th Apr 20214:40 pmRNSSecond Price Monitoring Extn
27th Apr 20214:35 pmRNSPrice Monitoring Extension
19th Apr 20215:25 pmRNSDirector/PDMR Shareholding
14th Apr 202112:18 pmRNSDirector/PDMR Shareholding
7th Apr 20214:40 pmRNSSecond Price Monitoring Extn
7th Apr 20214:35 pmRNSPrice Monitoring Extension
1st Apr 202112:48 pmRNSHolding(s) in Company
1st Apr 20219:34 amRNSInvestor Presentation
1st Apr 20217:40 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.